Detection of Pulmonary Embolism With CECT

This study has been completed.

Sponsored by:	Bracco Diagnostics, Inc
Information provided by:	Bracco Diagnostics, Inc
ClinicalTrials.gov Identifier:	NCT00351754

Purpose

To compare the vascular enhancement of the two contrast agents in pulmonary Multi-detector CTA

Condition	Intervention	Phase
Pulmonary Embolism	Drug: Isovue	Phase IV

MedlinePlus related topics: Pulmonary Embolism

Drug Information available for: Iodixanol Iopamidol

Study Type:	Interventional
Study Design:	Diagnostic, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Detection of Pulmonary Embolism Comparing Isovue-370 and Visipaque 320 Using 64-Slice Multi-Detector Computed Tomographic Angiography

Further study details as provided by Bracco Diagnostics, Inc:

Primary Outcome Measures:

Secondary Outcome Measures:

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00351754

Locations

United States, New Jersey
Bracco Diagnostics, Inc.
Princeton, New Jersey, United States, 08540

Sponsors and Collaborators

Bracco Diagnostics, Inc

Investigators

Study Director:

Steve Sireci, M.D.

Bracco Diagnostics

More Information

Study ID Numbers:	IOP 106
Study First Received:	June 30, 2006
Last Updated:	January 3, 2008
ClinicalTrials.gov Identifier:	NCT00351754
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Embolism and Thrombosis
Pulmonary Embolism
Respiratory Tract Diseases
Embolism

Lung Diseases
Vascular Diseases
Thrombosis

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009